FIRST ALPHA-RADIATION CANCER TREATMENT FOR SOLID TUMORS

Uzi Sofer, CEO and Chairman, Alpha Tau Medical, Tel Aviv, Israel

- **Investment Rational**
  Alpha Tau has developed the first alpha-radiation-based cancer treatment for all solid tumors. The treatment minimizes side effects while activating the immune system. In clinical trials, tumors shrank in 100% and resolved entirely in over 70% of the cases. Alpha Tau is led by brilliant scientists and experienced medtech-industry professionals, that have already established numerous clinical collaborations worldwide.

- **Business Strategy**
  The Alpha DaRT treatment does not require capital equipment and is delivered in a single minimally-invasive outpatient procedure using disposable easy-to-use applicators. As the applicators production is based on a personalized treatment plan, the company’s business model rests on the sale of the applicators to medical facilities that will perform the procedures.

- **Core Technology**
  Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) has shown to destroy any solid tumor without causing damage to surrounding tissue and the body as a whole. Unlike other radiotherapy, Alpha DaRT is based on high-energy alpha radiation which is substantially more potent and local, creating double-strand DNA breaks. Clinical results can be achieved within a short period of only 2 weeks.

- **Product Profile/Pipeline**
  With 9.6 million cancer deaths globally in 2018, the medical community seeks a solution that enables an effective and low-toxicity treatment. As the only technology that enables alpha radiation for solid tumors, Alpha DaRT is drawing significant attention. Over 70 clinical collaborations with leading cancer centers worldwide have been initiated for various indications, including breast, pancreatic, prostate and lung cancer. The company has established subsidiaries in the US and in Japan to enable optimized local manufacturing and distribution.

- **What’s Next?**
  Within the next few months, Alpha Tau is expected to initiate 7 new clinical trials in the US, Europe and Japan, and to establish a new production facility near Boston. The company has entered a major research collaboration with TAU, MSK, BGU, McGill and University of Montreal. Commercialization in Europe is expected by the end of 2019.